Geron Corporation GERN

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen

Geron stock has recovered over the past year but is still sitting on a steep decline over three years, while the valuation checks currently lean toward the shares looking inexpensive relative to fundamentals. Over the last three years, Geron has delivered a return of about 51% in decline, which signals that long term holders have faced significant capital pressure despite more recent gains. Expectations for Geron's ability to convert its pipeline into sustainable cash flows can support the...

Why Geron Stock Is Back in Focus After Fresh Guidance Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and half year 2026 results on 5 August, including updated revenue and net loss figures. See our latest analysis for Geron. Geron’s latest guidance and earnings update landed alongside a share price of $1.48, with a 7 day share price return of 14.73% and a 1 year total shareholder return of 15.62%. The...

In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$20.32 million, while also filing a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an ESOP. Investors now have an initial full-year 2026 view on RYTELO, with Geron guiding to net product revenue between US$220 million and US$240...

Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.

Moby summary of Geron Corporation's Q2 2026 earnings call

Achieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Officer Company to

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webc